Development of axitinib for pancreatic cancer discontinued
Pfizer is discontinuing a phase 3 study of axitinib for the treatment of advanced pancreatic cancer. An analysis by an independent data safety monitoring board demonstrated that there was no improvement in survival among patients treated with axitininb plus gemcitabine versus those treated with gemcitabine alone.
Pfizer is discontinuing a phase 3 study of axitinib for the treatment of advanced pancreatic cancer. An analysis by an independent data safety monitoring board demonstrated that there was no improvement in survival among patients treated with axitininb plus gemcitabine versus those treated with gemcitabine alone.
In a previous phase 2 study, patients treated with axitinib plus gemcitabine demonstrated a median overall survival of 6.9 months (95% CI, 5.3–10.1) versus 5.6 months (95% CI, 3.9–8.8) among those treated with gemcitabine alone. The HR for survival in patients treated with axitinib plus gemcitabine versus gemcitabine alone was 0.71 (95% CI, 0.44–1.13), a nonsignificant difference.
Phase 3 trials of axitinib for the second-line treatment of renal cell carcinoma are still ongoing.
Source
Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomized phase 2 study. Lancet. 2008;371:2101–2108
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
